FDA Approves Gilead Sciences, Inc.'s Sovaldi, A $1,000-A-Day Hepatitis C Pill

... disease is the nation's leading cause of liver cancer and liver transplantation, and in recent years has surpassed HIV/AIDS as a cause of death. The current standard of care for HCV involves up to 48 weeks of therapy with a pegylated interferon ...

http://www.biospace.com/news_story.aspx?StoryID=317991&full=1